Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DGAP-Adhoc : Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares

08/02/2021 | 05:33am EDT
DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous 
Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and 
Exchange Commission for a Proposed Offering of American Depositary Shares 
02-Aug-2021 / 11:32 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces 
that it confidentially submitted a Registration Statement on Form F-1 ("Registration Statement") with the U.S. 
Securities and Exchange Commission ("SEC") for a proposed offering and sale in the United States of shares of Evotec 
represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the 
final number of ADSs to be offered and their price have not yet been determined. 
Evotec's shares are listed on the regulated market of the Frankfurt Stock Exchange in Germany with additional admission 
obligations of the Prime Standard Segment. Evotec will seek a secondary listing of the ADSs on the Nasdaq Global Select 
Market in the United States under the ticker symbol "EVO". The new shares underlying the ADSs will be issued from 
Evotec's authorized capital. The first day of trading of the ADSs is expected to occur during the second half of 2021, 
however, this timing remains subject to change. 
The ADSs referred to in this announcement are to be offered only by means of a registration statement on Form F-1 
approved by the SEC. In accordance with applicable capital markets requirements, Evotec will announce when the 
registration statement has been approved by the SEC, including further details, such as final number and price of ADS. 
- End of the ad hoc release - 
This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any 
offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration 
requirements of the U.S. Securities Act of 1933, as amended ("Securities Act"), and other applicable securities laws. 
This announcement is being issued in accordance with Rule 135 under the Securities Act and other applicable securities 
laws. This public disclosure of inside information does not constitute a prospectus. 
This announcement contains forward-looking statements concerning future events, including the proposed offering and 
listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," 
"might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are 
intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. 
These forward-looking statements are based on the information available to, and the expectations and assumptions deemed 
reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will 
prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions 
and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond 
the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or 
revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with 
respect thereto or any change in events, conditions or circumstances on which any statement is based. 
Contact: 
Dr Werner Lanthaler, Chief Executive Officer 
Evotec SE 
Manfred Eigen Campus 
Essener Bogen 7 
22419 Hamburg, Germany 
Phone: +49.(0)40.560 81-242 
Email: werner.lanthaler@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
02-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1223297 
 
End of Announcement  DGAP News Service 
=------------ 

1223297 02-Aug-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223297&application_name=news 
 

(END) Dow Jones Newswires

August 02, 2021 05:32 ET (09:32 GMT)

All news about EVOTEC SE
10/27EVOTEC : Buy rating from Warburg Research
MD
10/27EVOTEC : Deutsche Bank reaffirms its Neutral rating
MD
10/27EVOTEC SE : Translational BRIDGE beLAB2122 in collaboration with Bristol Myers Squibb iden..
PU
10/27Evotec announces first funded projects of translational BRIDGE beLAB1407 in collaborati..
PU
10/26German biotech Evotec seeks over $9 bln valuation in U.S. IPO
RE
10/26German drug developer Evotec seeks over $9 bln valuation in U.S. IPO
RE
10/26Evotec SE announces launch of public offering of American Depositary Shares
PU
10/26EVOTEC SE : Announces launch of public offering of American Depositary Shares
EQ
10/26PRESS RELEASE : Evotec SE: Announces launch of public offering of American Depositary Shar..
DJ
10/26EVOTEC : Gets a Buy rating from Warburg Research
MD
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 564 M 654 M 654 M
Net income 2021 54,4 M 63,1 M 63,1 M
Net Debt 2021 72,0 M 83,6 M 83,6 M
P/E ratio 2021 86,2x
Yield 2021 -
Capitalization 6 909 M 8 007 M 8 019 M
EV / Sales 2021 12,4x
EV / Sales 2022 10,8x
Nbr of Employees 3 914
Free-Float 87,9%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 41,91 €
Average target price 40,01 €
Spread / Average Target -4,52%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Iris L÷w-Friedrich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE38.41%8 007
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528